In addition to NSCLC and certain types of lymphomas, ALK-EML4 fusions have been reported in inflammatory myofibroblastic tumors, papillary thyroid cancer, breast cancer, and colorectal cancer [21,22,23]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.